Case Reports

Idiopathic Granulomatous Lobular Mastitis: A Mimicker of Inflammatory Breast Cancer

Author and Disclosure Information

Background: Idiopathic granulomatous lobular mastitis (IGLM) is a rare, chronic inflammatory breast disease without a known etiology. Even though the current literature proposes several treatment strategies, there is no universal consensus for long-term management.

Case Presentation: A 43-year-old White woman (gravida 5, para 4) presented with a 2-week history of right lower outer quadrant breast tenderness, heaviness, warmth, and redness. Mammography and ultrasound were concerning for inflammatory breast cancer. Biopsies returned as granulomatous mastitis without malignancy. After 8 months of unsuccessful therapy with prednisone and methotrexate, surgeons excised the breast tissue. Cultures and special stains were negative for other organisms. At the 7-month follow-up, no evidence of recurrence was seen.

Conclusions: As there remains no consensus behind the etiology or management of IGLM, our case demonstrates a reasonable and successful stepwise treatment beginning with medical therapy before proceeding to surgical cure. Because of possible malignancy risk with chronic IGLM, patients should not delay surgical excision if their condition remains refractory to medical therapy alone.


 

References

Idiopathic granulomatous lobular mastitis (IGLM) is a rare, chronic inflammatory breast disease first described in 1972.1 IGLM usually affects women during reproductive years and has similar clinical features to breast cancer.2 Ultrasonography and mammography yield nonspecific results and cannot adequately differentiate between malignancy and inflammation.3 Magnetic resonance imaging (MRI) is known to be more sensitive in detecting lesions in dense breasts; however, it does not differentiate between granulomatous lesions and other disorders.4,5 Histopathology is the gold standard for diagnosis.1-12

Infectious and autoimmune causes of granulomatous mastitis must be excluded before establishing an IGLM diagnosis. The clinical quandary that remains is how to adequately manage the disease. Although there are no defined treatment guidelines, current literature has proposed a multimodal strategy.6,9 In this report, we describe a case of IGLM successfully treated with surgical excision after failed medical therapy.

Case Presentation

A 43-year-old gravida 5, para 4 White woman presented with a 2-week history of right breast tenderness, heaviness, warmth, and redness that was refractory to cephalexin and dicloxacillin. She had no personal or family history of breast cancer; never had breast surgery and breastfed all 4 children.

figures 1-2

An examination of the right breast demonstrated erythema and an 8-cm tender mass in the right lower outer quadrant but no skin retraction or dimpling (Figure 1). The mammography, concerning for inflammatory breast cancer, was category BI-RADS 4 and demonstrated a suspicious right axillary lymph node (Figure 2).

figure 3

A core needle breast biopsy revealed granulomatous mastitis (Figure 3A), without evidence of malignancy. Rheumatology and endocrinology excluded secondary causes of granulomatous mastitis (ie, sarcoidosis, tuberculosis, granulomatosis with polyangiitis, and other autoimmune conditions). A pituitary MRI to assess an elevated serum prolactin level showed no evidence of microadenoma.

After a prolonged course of 8 months of unsuccessful therapy with prednisone and methotrexate, the patient was referred for surgical excision. Culture and special stains (Gram stain, periodic acid-Schiff stain, acid-fast Bacillus culture, Fite stain, and Brown and Benn stain) of the breast tissue were negative for organisms (Figure 3B). Seven months after excision the patient was doing well and had no evidence of recurrence.

Pages

Recommended Reading

FDA approves Yuflyma as ninth adalimumab biosimilar
Federal Practitioner
Scientists discover variants, therapy for disabling pansclerotic morphea
Federal Practitioner
EULAR systemic sclerosis recommendations now include immunosuppressants
Federal Practitioner
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
Federal Practitioner
Systemic JIA and AOSD are the same disease, EULAR says
Federal Practitioner
Girls with congenital diaphragmatic hernia have lower survival rates
Federal Practitioner
Can a repurposed Parkinson’s drug slow ALS progression?
Federal Practitioner
FDA approves ritlecitinib for ages 12 and up for alopecia areata
Federal Practitioner
Myasthenia gravis drug gets FDA nod
Federal Practitioner
FDA okays first-ever new drug for rare bone disorder
Federal Practitioner